SEP 07, 2016 01:30 PM PDT

Manipulating the Microbiome to Prevent and Treat Infection

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Professor of Internal Medicine and Pathology, University of Iowa
    Biography
      Dr. Diekema is a Professor of Internal Medicine and Pathology at the University of Iowa Carver College of Medicine. After graduating from Vanderbilt University School of Medicine, Dr. Diekema did an internal medicine residency at the University of Virginia, and completed fellowships in infectious diseases, hospital epidemiology and medical microbiology at the University of Iowa, where he also received an MS in Preventive Medicine.
      Dr. Diekema currently serves as director of the Division of Infectious Diseases at the University of Iowa Carver College of Medicine, associate director of the University of Iowa Hospital Clinical Microbiology Laboratory, the associate hospital epidemiologist at University of Iowa Healthcare.
      Dr. Diekema's clinical and research interests include several aspects of healthcare epidemiology, including the epidemiology of invasive fungal infections in hospitalized patients, and the epidemiology of antimicrobial resistance. He has served on national committees that establish standards in clinical microbiology and infection prevention, including the Clinical and Laboratory Standards Institute (CLSI) and the CDC's Healthcare Infection Control Practices Advisory Committee (HICPAC), of which he is currently co-chair. He is also the immediate past-president of the Society for Healthcare Epidemiology of America (SHEA).

    Abstract:

    Healthcare associated infections can be a consequence of a microbiome alteration. Increasingly, treatment and prevention strategies focus on manipulating host microbiota, the two most common examples being (1) suppression of certain skin and mucosal microbiota, and (2) preservation or restoration of intestinal microbial communities.

    After this presentation, participants should be able to:  

    (a) discuss the evidence in support of chlorhexidine application to the skin and oropharynx of hospitalized patients to prevent infection
    (b) implement interventions to reduce the likelihood of Clostridium difficile recurrence after host exposure to antimicrobial agents.
     


    Show Resources
    You May Also Like
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...
    Show Resources